1-[4-(methylthio)butyl]cyclopentanecarboxylic acid | 220878-48-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 1-[4-(methylthio)butyl]cyclopentanecarboxylic acid
• 英文别名: 1-(4-methylsulfanylbutyl)cyclopentane-1-carboxylic acid
• CAS: 220878-48-8
• 化学式: C₁₁H₂₀O₂S
• 分子量: 216.345
• InChiKey: JSYRKEIKVJOFDD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  62.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-[4-(methylthio)butyl]cyclopentanecarboxylic acid 在 sodium hydroxide 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 15.0h， 生成 (S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-{[1-(4-methylsulfanyl-butyl)-cyclopentanecarbonyl]-amino}-propionic acid
  参考文献：
  名称：

  N-Cycloalkanoyl-l-Phenylalanine Derivatives as VCAM/VLA-4 Antagonists

  摘要：

  A systematic structure-activity relationship investigation of the lead compound I resulted the identification of several N-[(substituted alkyl)cycloalkanoyl]-4-[((2,6-dichlorophenyl)carbonyl)amino]-L-phenylalanine derivatives as potent VCAM/VLA-4 antagonists. The data are consistent with a model of these compounds in which these alkanoylphenylalanines reside in a compact gauche (-) bioactive conformation. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00386-4
• 作为产物：
  描述：

  环戊烷甲酸甲酯 在 sodium hydroxide 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 45.0h， 生成 1-[4-(methylthio)butyl]cyclopentanecarboxylic acid
  参考文献：
  名称：

  N-Cycloalkanoyl-l-Phenylalanine Derivatives as VCAM/VLA-4 Antagonists

  摘要：

  A systematic structure-activity relationship investigation of the lead compound I resulted the identification of several N-[(substituted alkyl)cycloalkanoyl]-4-[((2,6-dichlorophenyl)carbonyl)amino]-L-phenylalanine derivatives as potent VCAM/VLA-4 antagonists. The data are consistent with a model of these compounds in which these alkanoylphenylalanines reside in a compact gauche (-) bioactive conformation. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00386-4

文献信息

• Thioamide derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US06288267B1

  公开（公告）日：2001-09-11

  It has been discovered that compounds of the formula: and the pharmaceutically acceptable salts and esters thereof wherein X and Y are as defined below, inhibit the binding of VCAM-1 to VLA-4 and are useful in treating inflammation associated with chronic inflammatory diseases such as rheumatoid arthritis (RA), multiple sclerosis, (MS), asthma, and inflammatory bowel disease (I BD).

  已发现以下化合物的公式： 及其药用可接受的盐和酯，其中X和Y的定义如下，抑制VCAM-1与VLA-4的结合，并且在治疗与慢性炎症性疾病如类风湿性关节炎（RA）、多发性硬化（MS）、哮喘和炎症性肠病（IBD）相关的炎症方面是有用的。
• Diephenyl carbocyclic thioamide derivatives
  申请人：——

  公开号：US20010041799A1

  公开（公告）日：2001-11-15

  It has been discovered that compounds of the formula: 1 and the pharmaceutically acceptable salts and esters thereof wherein X and Y are as defined below, inhibit the binding of VCAM-1 to VLA-4 and are useful in treating inflammation associated with chronic inflammatory diseases such as rheumatoid arthritis (RA), multiple sclerosis, (MS), asthma, and inflammatory bowel disease (I BD).

  已发现以下化合物的公式：1及其药学上可接受的盐和酯，其中X和Y的定义如下，能够抑制VCAM-1与VLA-4的结合，并且适用于治疗与慢性炎症性疾病相关的炎症，例如类风湿性关节炎（RA），多发性硬化症（MS），哮喘和炎症性肠病（I BD）。
• PHENYL-KETO-IMIDAZOLIDINE THIOAMIDE DERIVATIVES
  申请人：——

  公开号：US20020010338A1

  公开（公告）日：2002-01-24

  It has been discovered that compounds of the formula: 1 and the pharmaceutically acceptable salts and esters thereof wherein X and Y are as defined below, inhibit the binding of VCAM-1 to VLA-4 and are useful in treating inflammation associated with chronic inflammatory diseases such as rheumatoid arthritis (RA), multiple sclerosis, (MS), asthma, and inflammatory bowel disease (I BD).

  已经发现了以下化合物的公式1及其药学上可接受的盐和酯，其中X和Y的定义如下，可以抑制VCAM-1与VLA-4的结合，并且在治疗与慢性炎症性疾病相关的炎症方面非常有用，如类风湿性关节炎（RA），多发性硬化症（MS），哮喘和炎症性肠病（IBD）。
• Diphenyl heterocyclic thioamide derivatives
  申请人：——

  公开号：US20020040148A1

  公开（公告）日：2002-04-04

  It has been discovered that compounds of the formula: 1 and the pharmaceutically acceptable salts and esters thereof wherein X and Y are as defined below, inhibit the binding of VCAM-1 to VLA-4 and are useful in treating inflammation associated with chronic inflammatory diseases such as rheumatoid arthritis (RA), multiple sclerosis, (MS), asthma, and inflammatory bowel disease (I BD).

  已经发现以下化合物的公式：1及其药学上可接受的盐和酯，其中X和Y的定义如下，可以抑制VCAM-1与VLA-4的结合，并且在治疗与慢性炎症性疾病相关的炎症方面非常有用，例如类风湿性关节炎（RA），多发性硬化症（MS），哮喘和炎症性肠病（I BD）。
• Heterocyclic thioamide derivatives
  申请人：——

  公开号：US20020052508A1

  公开（公告）日：2002-05-02

  It has been discovered that compounds of the formula: 1 and the pharmaceutically acceptable salts and esters thereof wherein X and Y are as defined below, inhibit the binding of VCAM-1 to VLA-4 and are useful in treating inflammation associated with chronic inflammatory diseases such as rheumatoid arthritis (RA), multiple sclerosis, (MS), asthma, and inflammatory bowel disease (IBD).

  已经发现了以下式子的化合物：1及其药用可接受的盐和酯，其中X和Y的定义如下，可以抑制VCAM-1与VLA-4的结合，并且有助于治疗与慢性炎症性疾病相关的炎症，例如类风湿性关节炎（RA），多发性硬化症（MS），哮喘和炎症性肠病（IBD）。